文献速递前列腺癌

围手术期阿帕他胺联合ADT对比单纯根治性前列腺切除术在高危局限性或局部晚期前列腺癌中的疗效:PROTEUS子研究

Treatment Effect of Perioperative (Neoadjuvant and Adjuvant) Apalutamide plus Androgen-deprivation Therapy Versus Radical Prostatectomy Alone in Patients with High-risk Localized or Locally Advanced Prostate Cancer from the PROTEUS Substudy.
PubMed 文献 · Eur Urol · 2026-10-24

该子研究纳入408例新诊断高危局限性或局部晚期前列腺癌患者,随机1:3接受围手术期阿帕他胺联合ADT或单纯根治性前列腺切除术。结果显示联合治疗显著改善无事件生存(3年无事件率63% vs 41%,HR 0.38,95%CI 0.26-0.55,p<0.001),并延迟后续治疗需求。

要点

  • 围手术期阿帕他胺联合ADT较单纯手术显著改善无事件生存(HR 0.38)。
  • 联合治疗组3年无事件生存率为63%,单纯手术组为41%。
  • 联合治疗使后续治疗风险降低71%(HR 0.29,95%CI 0.20-0.43)。

核心结论

  • 围手术期阿帕他胺联合ADT较标准根治性前列腺切除术显著改善无事件生存并延迟后续治疗。

研究设计与样本

  • PROTEUS子研究为随机、开放标签研究,纳入408例新诊断高危局限性或局部晚期前列腺癌患者。
  • 患者按1:3随机接受围手术期阿帕他胺(240 mg/d)联合ADT(术前及术后各6个28天周期)或单纯根治性前列腺切除术。
  • 主要终点为无事件生存(EFS),定义为至生化失败、局部/区域复发、远处转移或死亡的时间。

主要发现

  • 联合治疗组中位EFS未达到,单纯手术组为19.1个月;估计3年无事件率分别为63%和41%(HR 0.38,95%CI 0.26-0.55,p<0.001)。
  • 限制性平均生存时间分析显示,前36个月平均无事件时间联合组为31.7个月(95%CI 30.3-33.1),单纯手术组为20.7个月(95%CI 19.1-22.4),差异11.0个月(95%CI 8.8-13.1,p<0.001)。
  • 常规影像或PSMA PET评估的无转移生存(MFS) favoring 联合治疗(3年无事件率87% vs 78%;HR 0.49,95%CI 0.26-0.90,p=0.019)。
  • 联合治疗组后续治疗风险降低71%(HR 0.29,95%CI 0.20-0.43,p<0.001)。
  • 常规影像评估的MFS两组无差异(3年无事件率94% vs 92%;HR 0.74,95%CI 0.30-1.82,p=0.5)。

关键数值与推荐

  • 围手术期阿帕他胺联合ADT方案:阿帕他胺240 mg/d联合ADT,术前及术后各6个28天周期。
  • 3-4级治疗中出现的不良事件发生率:联合组31%(31例),单纯手术组22%(62例)。

临床怎么用

  • 对于适合手术及1年系统治疗的高危局限性或局部晚期前列腺癌患者,围手术期阿帕他胺联合ADT可作为新的治疗选择。

局限性

  • 由于风险比随时间变化,比例风险假设不成立,EFS的主要分析需谨慎解读,研究进行了事后限制性平均生存时间分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The blinded placebo-controlled PROTEUS (Perioperative Treatment with Erleada United with Surgery) study demonstrated that adding 1-yr perioperative apalutamide plus androgen-deprivation therapy (ADT) benefited patients with high-risk localized prostate cancer or locally advanced prostate cancer (HR-LPC/LAPC) who were undergoing radical prostatectomy with pelvic lymph node dissection (RP). OBJECTIVE: This substudy evaluated 1-yr perioperative apalutamide plus ADT versus standard-of-care (SOC) RP. DESIGN, SETTING, AND PARTICIPANTS: Patients with newly diagnosed HR-LPC/LAPC were randomized 1:3 to open-label perioperative apalutamide (240 mg/d) plus ADT (six 28-d cycles before and after RP) or RP. OUTCOMES MEASUREMENTS AND STATISTICAL ANALYSIS: The primary end point was event-free survival (EFS), defined as time to biochemical failure, local/regional recurrence, distant metastasis, or death. Secondary/other end points included metastasis-free survival (MFS) by conventional or prostate-specific membrane antigen positron emission tomography (PSMA PET) imaging, MFS by conventional imaging, and time to first subsequent therapy; p values were nominal. Time-to-event end points were analyzed with the Kaplan-Meier method and stratified Cox proportional hazards models adjusted for the randomization stratification factors to estimate hazard ratios (HRs) with 95% confidence intervals (CIs). RESULTS AND LIMITATIONS: In total, 408 patients (median age 66 yr [interquartile range 62-71]) were randomized: perioperative apalutamide plus ADT, n = 102; RP, n = 306. Median follow-up was 37.4 mo in patients without EFS events. Perioperative apalutamide plus ADT significantly improved EFS compared with RP alone (median not reached vs 19.1 mo; estimated 3-yr event-free rates 63% vs 41%; HR 0.38; 95% CI 0.26-0.55; p < 0.001). Because of the nonconstant HR over time, indicating that the proportional hazards assumption was not met, a post hoc restricted mean survival time analysis was performed. This analysis estimated that the average event-free time during the first 36 mo was 31.7 mo (95% CI 30.3-33.1) with perioperative apalutamide plus ADT versus 20.7 mo (95% CI 19.1-22.4) with RP alone, a difference of 11.0 mo (95% CI 8.8-13.1; p < 0.001). MFS by conventional or PSMA PET imaging favored perioperative apalutamide plus ADT over RP alone (estimated 3-yr event-free rates 87% vs 78%; HR 0.49; 95% CI 0.26-0.90; p = 0.019), and the hazard of subsequent therapy was reduced by 71% (HR 0.29; 95% CI 0.20-0.43; p < 0.001). MFS by conventional imaging showed no difference between study groups (estimated 3-yr event-free rates 94% vs 92%; HR 0.74; 95% CI 0.30-1.82; p = 0.5). Grade 3-4 treatment-emergent adverse events occurred in 31 patients (31%) receiving perioperative apalutamide plus ADT versus 62 patients (22%) receiving RP. CONCLUSIONS: Perioperative apalutamide plus ADT improved EFS and delayed subsequent therapy compared with SOC. Together with the blinded PROTEUS main study, these results support perioperative apalutamide plus ADT as a new therapeutic option for selected patients with HR-LPC/LAPC who are fit for surgery and 1-yr systemic therapy.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Briganti A, Steuber T, Shore ND, et al. Treatment Effect of Perioperative (Neoadjuvant and Adjuvant) Apalutamide plus Androgen-deprivation Therapy Versus Radical Prostatectomy Alone in Patients with High-risk Localized or Locally Advanced Prostate Cancer from the PROTEUS Substudy. Eur Urol. 2026. PMID: 42966675. doi:10.1016/j.eururo.2026.10.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。